Blog Viewer

Second Intravenous Immunoglobulin Dose in Patients with Guillain-Barré Syndrome with Poor Prognosis (SID-GBS): A Double-Blind, Randomised, Placebo-Controlled Trial

By Currents Editor posted 06-30-2021 09:47

  

The Lancet Neurology (04/01/21)  DOI: 10.1016/S1474-4422(20)30494-4

Walgaard, Christa; Jacobs, Bart C; Lingsma, Hester F; et al.

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30494-4/fulltext 

New research finds no benefit but a risk of serious adverse events from a second intravenous immunoglobulin dose (SID) for patients with Guillain-Barré syndrome with a poor prognosis. Investigators had investigated the efficacy of a SID in this population, as treatment with one standard dose of I.V. immunoglobulin is not sufficient for some patients with severe Guillain-Barré syndrome. The randomized, double-blind study included patients with Guillain-Barré syndrome on their first day of standard I.V. immunoglobulin treatment (2 g/kg over 5 days). Using the modified Erasmus Guillain-Barré syndrome Outcome Score, patients with a poor prognosis score were randomized to receive SID or to placebo, 7-9 days after inclusion. Among the 93 patients with a poor prognosis who were included in the modified intention-to-treat analysis, 49 received SID and 44 received placebo. At 4 weeks, the adjusted common odds ratio for improvement on the Guillain-Barré syndrome disability score was 1.4. According to the data, more than twice as many patients who received a SID experienced serious adverse events in the first 30 days, including thromboembolic events, at 35% vs. 16% in the placebo group. In addition, four patients in the SID group died, 13-24 weeks after randomization. Based on the findings, the researchers say a SID should not be considered for the treatment of Guillain-Barré syndrome with a poor prognosis, and they call for more research into other immune modulators for these patients.

#LiteratureWatch

FURTHER READING
Donald Langan, MD, PharmD, Alexandra Schroeder, PA-C Ischemic strokes in younger adults, those 18 to 50 years old, account for approximately 10% to 15% of all ischemic strokes. Risk factors for stroke between younger and older patients tend to be similar. Younger patients suffer from cardioembolic ...
During the 2nd annual World Coma Day , NCS and the Curing Coma ® Campaign invited patients and their providers to share their stories of recovery, in video format. Below you will hear the story of little Eli. Elijiah (Eli) and his parents Victor and Jannette, as they discuss an April 2021 car crash ...
Clinical Neurophysiology (05/06/22) DOI: 10.1016/j.clinph.2022.04.018 Amorim, Edilberto; Firme, Marcos S.; Zheng, Wei-Long; et al. https://www.sciencedirect.com/science/article/abs/pii/S1388245722002619 A recent study sought to estimate the prevalence of seizures and ictal-interictal continuum ...